Viatris indicators agreements with Biocon on $815m stake sale

Viatris has signed definitive agreements for the sale of its fairness stake in Biocon Biologics to Biocon for $815m.

Viatris will promote all of its convertible most well-liked fairness in Biocon Biologics. The deal worth includes $415m in newly issued Biocon fairness shares and $400m in money.

The newly issued shares might be listed and traded on the Nationwide Inventory Change of India. They are going to be topic to a lock-up interval of six months, and the general transaction worth might be adjusted for relevant taxes.

The agreements additionally present for an earlier finish to the biosimilars non-compete restrictions that had been carried out in 2022 after Viatris bought its biosimilars portfolio to Biocon Biologics.

These restrictions will conclude at closing for markets exterior the US, whereas within the US they’ll stay in impact till November 2026.

The deal is anticipated to be finalised within the first quarter of 2026, pending the fulfilment of all closing situations.

Viatris has appointed Citi as its monetary advisor, with Cravath, Swaine & Moore and Khaitan & Co offering authorized counsel.

Viatris CEO Scott Smith acknowledged: “Monetising the worth of our fairness stake in Biocon Biologics and regaining entry to the biosimilars market globally supplies vital extra optionality as we proceed to construct a portfolio of generics, established manufacturers and revolutionary manufacturers that may contribute to our future development.”

Viatris is a world healthcare firm with operations headquartered in Pittsburgh within the US, with extra centres in Hyderabad, India and Shanghai, China.

The corporate provides medicines a billion sufferers worldwide every year, providing a broad portfolio that covers each generics and branded therapies.

It helps healthcare wants, from acute to persistent situations, by means of its world provide chain and scientific experience.

In October 2024, Lexicon Prescription drugs entered right into a licensing settlement with Viatris, granting the latter unique rights to commercialise sotagliflozin in all indications exterior the US and Europe.

“Viatris indicators agreements with Biocon on $815m stake sale ” was initially created and revealed by Pharmaceutical Expertise, a GlobalData owned model.

The knowledge on this website has been included in good religion for common informational functions solely. It’s not supposed to quantity to recommendation on which it’s best to rely, and we give no illustration, guarantee or assure, whether or not specific or implied as to its accuracy or completeness. It’s essential to acquire skilled or specialist recommendation earlier than taking, or refraining from, any motion on the idea of the content material on our website.